206 related articles for article (PubMed ID: 3141503)
1. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
[TBL] [Abstract][Full Text] [Related]
2. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
[TBL] [Abstract][Full Text] [Related]
3. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
Glennie MJ; McBride HM; Worth AT; Stevenson GT
J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
[TBL] [Abstract][Full Text] [Related]
4. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
5. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
6. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
8. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
[TBL] [Abstract][Full Text] [Related]
9. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
10. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
11. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
[TBL] [Abstract][Full Text] [Related]
12. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
13. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
14. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
15. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
16. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Flavell DJ; Cooper S; Morland B; Flavell SU
Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
Flavell DJ; Cooper S; Morland B; French R; Flavell SU
Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
20. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.
Glennie MJ; McBride HM; Stirpe F; Thorpe PE; Worth AT; Stevenson GT
J Exp Med; 1987 Jul; 166(1):43-62. PubMed ID: 3110351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
